The United States Patent and Trademark Office (USPTO) has issued patent US12582712B2 to Scholar Rock, Inc. This patent grants exclusive rights for a method of making anti-pro/latent myostatin antibodies. The abstract indicates the invention relates to antibodies that specifically bind proMyostatin and/or latent Myostatin, along with their associated uses.

This patent grant signifies a new intellectual property asset for Scholar Rock, Inc. in the field of biopharmaceuticals. While this is a patent grant and not a regulatory rule, it may impact future research, development, and commercialization activities by other entities working with myostatin antibodies. Compliance officers in the pharmaceutical sector should note this development as it pertains to intellectual property landscapes in therapeutic antibody development.